BioStock: Medivir presents promising results in difficult-to-treat patient population
Medivir today presents new clinical data from its phase Ib/IIa study at ESMO GI in Munich. The company's candidate fostrox shows strongly improved results in combination with Lenvima for patients with advanced primary liver cancer, a difficult-to-treat patient group that currently lacks approved treatment options in the second line.
– We are particularly encouraged by the durable benefit, with patients remaining on treatment for much longer than expected. More than 10 months median time to progression is significantly longer than previously achieved with second-line treatment with Lenvima monotherapy or other treatment options, says Medivir's CEO Jens Lindberg.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
